JP2011528667A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011528667A5 JP2011528667A5 JP2011518952A JP2011518952A JP2011528667A5 JP 2011528667 A5 JP2011528667 A5 JP 2011528667A5 JP 2011518952 A JP2011518952 A JP 2011518952A JP 2011518952 A JP2011518952 A JP 2011518952A JP 2011528667 A5 JP2011528667 A5 JP 2011528667A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- branched
- alkyl
- benzo
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 methylenedioxy group Chemical group 0.000 claims 34
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 12
- 230000004044 response Effects 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 230000015654 memory Effects 0.000 claims 8
- 206010027175 Memory impairment Diseases 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 239000012491 analyte Substances 0.000 claims 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drugs Drugs 0.000 claims 5
- 230000007787 long-term memory Effects 0.000 claims 5
- 125000005418 aryl aryl group Chemical group 0.000 claims 4
- 125000004432 carbon atoms Chemical group C* 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 239000011232 storage material Substances 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 claims 2
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 claims 2
- 125000005605 benzo group Chemical group 0.000 claims 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 229940000406 drug candidates Drugs 0.000 claims 2
- 230000002708 enhancing Effects 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 claims 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 125000005545 phthalimidyl group Chemical group 0.000 claims 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000004306 triazinyl group Chemical group 0.000 claims 2
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 241001272567 Hominoidea Species 0.000 claims 1
- 241000288903 Lemuridae Species 0.000 claims 1
- 241000282553 Macaca Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Claims (24)
前記刺激に対する前記被検体の応答を評価する工程
を含む記憶剤の有効性を評定するための方法。 The method for assessing the effectiveness of the memory agent comprises assessing the response of the subject with respect to and the stimulus; presenting Engineering as a set of stimuli to the subject being administered the storage agent.
(式中、Y1、Y2、Y3およびY4は各々、独立して、-H;直鎖もしくは分枝C1〜C7 のアルキル、モノフルオロアルキルもしくはポリフルオロアルキル;直鎖もしくは分枝C2〜C7のアルケニルもしくはアルキニル;C3〜C7シクロアルキルもしくはC5〜C7シクロアルケニル;-F、-Cl、-Brもしくは-I;-NO2;-N3;-CN;-OR4、-SR4、-OCOR4、-COR4、-NCOR4、-N(R4)2、-CON(R4)2もしくは-COOR4;アリールもしくはヘテロアリールであるか;または隣接する炭素原子上に存在するY1、Y2、Y3およびY4のうちの任意の2つがメチレンジオキシ基を構成し得る;ここで、各R4は、独立して、-H;直鎖または分枝C1〜C7のアルキル、モノフルオロアルキルまたはポリフルオロアルキル;直鎖または分枝C2〜C7のアルケニルまたはアルキニル;C3〜C7シクロアルキル、C5〜C7シクロアルケニル、アリールまたはアリール(C1〜C6)アルキルである;
Aは、A’、直鎖もしくは分枝C1〜C7アルキル、アリール、ヘテロアリール、アリール(C1〜C6)アルキルまたはヘテロアリール(C1〜C6)アルキルであり;ここで、A’は、
であり、R1およびR2は各々、独立して、H、直鎖もしくは分枝C1〜C7アルキル、-F、-Cl、-Br、-I、-NO2または-CNであり;R3は、H、直鎖もしくは分枝C1〜C7アルキル、-F、-Cl、-Br、-I、-NO2、-CN、-OR6、アリールまたはヘテロアリールであり;R 6は、直鎖もしくは分枝C1〜C7アルキルまたはアリールである;
Bは、アリール、ピリジル、ピリダジニル、ピリミジニル、ピラジニル、トリアジニル、インドリジニル、インドール-4-イル、インドール-5-イル、インドール-6-イル、インドール-7-イル、イソインドリル、ベンゾ[b]フラン-4-イル、ベンゾ[b]フラン-5-イル、ベンゾ[b]フラン-6-イル、ベンゾ[b]フラン-7-イル、ベンゾ[b]チオフェン-4-イル、ベンゾ[b]チオフェン-5-イル、ベンゾ[b]チオフェン-6-イル、ベンゾ[b]チオフェン-7-イル、インダゾリル、ベンゾイミダゾリル、ベンゾ[b]チアゾリル、プリニル、イミダゾ[2,1-b]チアゾリル、キノリニル、イソキノリニル、キナゾリニル、2,1,3-ベンゾチアゾリル、フラニル、チエニル、ピロリル、オキサゾリル、チアゾリル、イミダゾリル、ピラゾリル、イソオキサゾリル、イソチアゾリル、オキサジアゾリル、トリアゾリル、チアジアゾリル、ベンゾオキサゾリル、ベンゾイソオキサゾリル、シンノリニル、キノキサリニル、1,8-ナフチリジニル、プテリジニル、またはフタルイミジルである;ただし、イミン結合の窒素原子に対してオルトの炭素原子(1つまたは複数)が、以下-F、-Cl、-Br、-I、-CN、メチル、エチルまたはメトキシの1つ以上でだけ置換され得るものとする;
nは、1〜4の整数(両端を含む)である;ここで、アリールは、フェニルまたはナフチルであり、以下:-F、-Cl、-Br、-I、-NO2、-CN、直鎖もしくは分枝C1〜C7アルキル、直鎖もしくは分枝C1〜C7モノフルオロアルキル、直鎖もしくは分枝C1〜C7ポリフルオロアルキル、直鎖もしくは分枝C2〜C7アルケニル、直鎖もしくは分枝C2〜C7アルキニル、C3〜C7シクロアルキル、C1〜C7モノフルオロシクロアルキル、C3〜C7ポリフルオロシクロアルキル、C5〜C7シクロアルケニル、-OR4、SR4、-OCOR4、-COR4、-NCOR4、-CO2R4、-CON(R4)2または(CH2)n-O-(CH2)mCH3の1つ以上で置換されたフェニルおよびナフチルを含む)
を有する化合物またはその薬学的に許容され得る塩からなる群より選択される1種類以上であり、好ましくは構造:
(式中、Meはメチルであり、cPentはシクロペンチルであり、第3炭素と第5炭素はS配置である)
を有する化合物からなる群より選択される1種類以上である、請求項1〜9いずれか記載の方法。 The memory agent has the structure:
(Each wherein, Y 1, Y 2, Y 3 and Y 4 are independently, -H; straight or alkyl branched C 1 -C 7, monofluoroalkyl or polyfluoroalkyl; straight chained or partial alkenyl or alkynyl of branch C 2 ~C 7; C 3 ~C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; -F, -Cl, -Br or -I; -NO 2; -N 3; -CN; -OR 4 , -SR 4 , -OCOR 4 , -COR 4 , -NCOR 4 , -N (R 4 ) 2 , -CON (R 4 ) 2 or -COOR 4 ; aryl or heteroaryl; or adjacent Any two of Y 1 , Y 2 , Y 3, and Y 4 present on the carbon atoms to form a methylenedioxy group; where each R 4 is independently -H; chain or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight or or alkenyl branched C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl Le is the C 5 -C 7 cycloalkenyl, aryl or aryl (C 1 ~C 6) alkyl;
A is A ′, linear or branched C 1 -C 7 alkyl, aryl, heteroaryl, aryl (C 1 -C 6 ) alkyl or heteroaryl (C 1 -C 6 ) alkyl; '
R 1 and R 2 are each independently H, linear or branched C 1 -C 7 alkyl, —F, —Cl, —Br, —I, —NO 2 or —CN; R 3 is H, linear or branched C 1 -C 7 alkyl, —F, —Cl, —Br, —I, —NO 2 , —CN, —OR 6 , aryl or heteroaryl ; R 6 Is linear or branched C 1 -C 7 alkyl or aryl;
B is aryl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indol-4-yl, indol-5-yl, indol-6-yl, indol-7-yl, isoindolyl, benzo [b] furan-4 -Yl, benzo [b] furan-5-yl, benzo [b] furan-6-yl, benzo [b] furan-7-yl, benzo [b] thiophen-4-yl, benzo [b] thiophene-5 - yl, benzo [b] thiophen-6-yl, benzo [b] thiophen-7-yl, indazolyl, Ben zo imidazolyl, benzo [b] thiazolyl, purinyl, imidazo [2,1-b] thiazolyl, quinolinyl, isoquinolinyl Quinazolinyl, 2,1,3-benzothiazolyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, tri Zoriru, thiadiazolyl, benzoxazolyl, Ben zo isoxazolyl, cinnolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, or is phthalimidyl; provided that the carbon atoms ortho to the nitrogen atom of the imine bond (s) but below -F, to -Cl, -Br, -I, -CN, shall methyl, may be only replacement but at least one ethyl or methoxy;
n is an integer of 1 to 4 inclusive; wherein aryl is phenyl or naphthyl, the following: -F, -Cl, -Br, -I , -NO 2, -CN, straight or branched C 1 -C 7 alkyl, straight-chain or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl , straight-chain or branched C 2 -C 7 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 7 monofluoroalkyl cycloalkyl, C 3 -C 7 polyfluoroalkyl cycloalkyl, C 5 -C 7 cycloalkenyl, - oR 4, SR 4, one of -OCOR 4, -COR 4, -NCOR 4 , -CO 2 R 4, -CON (R 4) 2 or (CH 2) n -O- (CH 2) m CH 3 Including phenyl and naphthyl substituted above)
Der one or more selected from a compound or group thereof consisting of pharmaceutically acceptable salts having is, preferably the structure:
(Wherein Me is methyl, cPent is cyclopentyl, and the third and fifth carbons are in S configuration)
One or more der Ru method according to any one of claims 1-9 selected from the group consisting of compounds having the.
前記被検体に刺激の組を提示する工程;および
前記刺激に対する前記被検体の応答を評価する工程
を含む、長期記憶増強因子としての記憶剤を試験するための方法。 Administering a serial憶剤nonhuman subjects;
Presenting a set of stimuli to the subject; and evaluating a response of the subject to the stimulus; a method for testing a memory agent as a long-term memory enhancing factor .
前記被検体に刺激の組を提示する工程、および
前記刺激に対する前記被検体の応答を評価する工程
を含む、長期記憶増強因子としての訓練プロトコルを試験するための方法。 Step of applying the training protocol to a subject; and the step of presenting a set of stimulus to the subject, and a step of assessing the response of the subject relative to <br/> the stimulus, as long-term memory enhancing factor Method for testing training protocols .
前記被検体に刺激の組を提示する工程、および
前記刺激に対する前記被検体の応答を評価する工程
を含む、薬物候補として記憶障害薬を同定するための方法。 Step assessing the memory impairment agent by administering memorize disorder agent to a non-human subject; step of presenting a set of stimulus to and the subject, and the response of the subject relative to <br/> the stimulus A method for identifying a memory impairment drug as a drug candidate comprising the step of evaluating.
(式中、Y1、Y2、Y3およびY4は各々、独立して、-H;直鎖もしくは分枝C1〜C7 のアルキル、モノフルオロアルキルもしくはポリフルオロアルキル;直鎖もしくは分枝C2〜C7のアルケニルもしくはアルキニル;C3〜C7シクロアルキルもしくはC5〜C7シクロアルケニル;-F、-Cl、-Brもしくは-I;-NO2;-N3;-CN;-OR4、-SR4、-OCOR4、-COR4、-NCOR4、-N(R4)2、-CON(R4)2もしくは-COOR4;アリールもしくはヘテロアリールであるか;または隣接する炭素原子上に存在するY1、Y2、Y3およびY4のうちの任意の2つがメチレンジオキシ基を構成し得る;ここで、各R4は、独立して、-H;直鎖または分枝C1〜C7のアルキル、モノフルオロアルキルまたはポリフルオロアルキル;直鎖または分枝C2〜C7のアルケニルまたはアルキニル;C3〜C7シクロアルキル、C5〜C7シクロアルケニル、アリールまたはアリール(C1〜C6)アルキルである;
Aは、A’、直鎖もしくは分枝C1〜C7アルキル、アリール、ヘテロアリール、アリール(C1〜C6)アルキルまたはヘテロアリール(C1〜C6)アルキルであり;ここで、A’は、
であり、R1およびR2は各々、独立して、H、直鎖もしくは分枝C1〜C7アルキル、-F、-Cl、-Br、-I、-NO2または-CNであり;R3は、H、直鎖もしくは分枝C1〜C7アルキル、-F、-Cl、-Br、-I、-NO2、-CN、-OR6、アリールまたはヘテロアリールであり;R 6は、直鎖もしくは分枝C1〜C7アルキルまたはアリールである;
Bは、アリール、ピリジル、ピリダジニル、ピリミジニル、ピラジニル、トリアジニル、インドリジニル、インドール-4-イル、インドール-5-イル、インドール-6-イル、インドール-7-イル、イソインドリル、ベンゾ[b]フラン-4-イル、ベンゾ[b]フラン-5-イル、ベンゾ[b]フラン-6-イル、ベンゾ[b]フラン-7-イル、ベンゾ[b]チオフェン-4-イル、ベンゾ[b]チオフェン-5-イル、ベンゾ[b]チオフェン-6-イル、ベンゾ[b]チオフェン-7-イル、インダゾリル、ベンゾイミダゾリル、ベンゾ[b]チアゾリル、プリニル、イミダゾ[2,1-b]チアゾリル、キノリニル、イソキノリニル、キナゾリニル、2,1,3-ベンゾチアゾリル、フラニル、チエニル、ピロリル、オキサゾリル、チアゾリル、イミダゾリル、ピラゾリル、イソオキサゾリル、イソチアゾリル、オキサジアゾリル、トリアゾリル、チアジアゾリル、ベンゾオキサゾリル、ベンゾイソオキサゾリル、シンノリニル、キノキサリニル、1,8-ナフチリジニル、プテリジニル、またはフタルイミジルである;ただし、イミン結合の窒素原子に対してオルトの炭素原子(1つまたは複数)が、以下-F、-Cl、-Br、-I、-CN、メチル、エチルまたはメトキシの1つ以上でだけ置換され得るものとする;
nは、1〜4の整数(両端を含む)である;ここで、アリールは、フェニルまたはナフチルであり、以下:-F、-Cl、-Br、-I、-NO2、-CN、直鎖もしくは分枝C1〜C7アルキル、直鎖もしくは分枝C1〜C7モノフルオロアルキル、直鎖もしくは分枝C1〜C7ポリフルオロアルキル、直鎖もしくは分枝C2〜C7アルケニル、直鎖もしくは分枝C2〜C7アルキニル、C3〜C7シクロアルキル、C1〜C7モノフルオロシクロアルキル、C3〜C7ポリフルオロシクロアルキル、C5〜C7シクロアルケニル、-OR4、SR4、-OCOR4、-COR4、-NCOR4、-CO2R4、-CON(R4)2または(CH2)n-O-(CH2)mCH3の1つ以上で置換されたフェニルおよびナフチルを含む)
を有する化合物またはその薬学的に許容され得る塩からなる群より選択される1種類以上であり、好ましくは構造:
(式中、Meはメチルであり、cPentはシクロペンチルであり、第3炭素と第5炭素はS配置である)
を有する化合物からなる群より選択される1種類以上である、請求項11〜16いずれか記載の方法。 The memory agent has the structure:
(Each wherein, Y 1, Y 2, Y 3 and Y 4 are independently, -H; straight or alkyl branched C 1 -C 7, monofluoroalkyl or polyfluoroalkyl; straight chained or partial alkenyl or alkynyl of branch C 2 ~C 7; C 3 ~C 7 cycloalkyl or C 5 -C 7 cycloalkenyl; -F, -Cl, -Br or -I; -NO 2; -N 3; -CN; -OR 4 , -SR 4 , -OCOR 4 , -COR 4 , -NCOR 4 , -N (R 4 ) 2 , -CON (R 4 ) 2 or -COOR 4 ; aryl or heteroaryl; or adjacent Any two of Y 1 , Y 2 , Y 3, and Y 4 present on the carbon atoms to form a methylenedioxy group; where each R 4 is independently -H; chain or branched C 1 -C 7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight or or alkenyl branched C 2 -C 7 alkynyl; C 3 -C 7 cycloalkyl Le is the C 5 -C 7 cycloalkenyl, aryl or aryl (C 1 ~C 6) alkyl;
A is A ′, linear or branched C 1 -C 7 alkyl, aryl, heteroaryl, aryl (C 1 -C 6 ) alkyl or heteroaryl (C 1 -C 6 ) alkyl; '
R 1 and R 2 are each independently H, linear or branched C 1 -C 7 alkyl, —F, —Cl, —Br, —I, —NO 2 or —CN; R 3 is H, linear or branched C 1 -C 7 alkyl, —F, —Cl, —Br, —I, —NO 2 , —CN, —OR 6 , aryl or heteroaryl ; R 6 Is linear or branched C 1 -C 7 alkyl or aryl;
B is aryl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indol-4-yl, indol-5-yl, indol-6-yl, indol-7-yl, isoindolyl, benzo [b] furan-4 -Yl, benzo [b] furan-5-yl, benzo [b] furan-6-yl, benzo [b] furan-7-yl, benzo [b] thiophen-4-yl, benzo [b] thiophene-5 - yl, benzo [b] thiophen-6-yl, benzo [b] thiophen-7-yl, indazolyl, Ben zo imidazolyl, benzo [b] thiazolyl, purinyl, imidazo [2,1-b] thiazolyl, quinolinyl, isoquinolinyl Quinazolinyl, 2,1,3-benzothiazolyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, tri Zoriru, thiadiazolyl, benzoxazolyl, Ben zo isoxazolyl, cinnolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, or is phthalimidyl; provided that the carbon atoms ortho to the nitrogen atom of the imine bond (s) but below -F, to -Cl, -Br, -I, -CN, shall methyl, may be only replacement but at least one ethyl or methoxy;
n is an integer of 1 to 4 inclusive; wherein aryl is phenyl or naphthyl, the following: -F, -Cl, -Br, -I , -NO 2, -CN, straight or branched C 1 -C 7 alkyl, straight-chain or branched C 1 -C 7 monofluoroalkyl, straight chained or branched C 1 -C 7 polyfluoroalkyl, straight chained or branched C 2 -C 7 alkenyl , straight-chain or branched C 2 -C 7 alkynyl, C 3 -C 7 cycloalkyl, C 1 -C 7 monofluoroalkyl cycloalkyl, C 3 -C 7 polyfluoroalkyl cycloalkyl, C 5 -C 7 cycloalkenyl, - oR 4, SR 4, one of -OCOR 4, -COR 4, -NCOR 4 , -CO 2 R 4, -CON (R 4) 2 or (CH 2) n -O- (CH 2) m CH 3 Including phenyl and naphthyl substituted above)
Der one or more selected from a compound or group thereof consisting of pharmaceutically acceptable salts having is, preferably the structure:
(Wherein Me is methyl, cPent is cyclopentyl, and the third and fifth carbons are in S configuration)
One or more der Ru, claims 11 to 16 The method of any one selected from the group consisting of compounds having the.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8194508P | 2008-07-18 | 2008-07-18 | |
US61/081,945 | 2008-07-18 | ||
PCT/US2009/051082 WO2010009453A1 (en) | 2008-07-18 | 2009-07-17 | Methods and systems for evaluating memory agents |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011528667A JP2011528667A (en) | 2011-11-24 |
JP2011528667A5 true JP2011528667A5 (en) | 2012-07-26 |
JP5789511B2 JP5789511B2 (en) | 2015-10-07 |
Family
ID=41550744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011518952A Expired - Fee Related JP5789511B2 (en) | 2008-07-18 | 2009-07-17 | Method and system for evaluation of memory agents |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2313098A4 (en) |
JP (1) | JP5789511B2 (en) |
KR (1) | KR20110049801A (en) |
CN (1) | CN102143749A (en) |
AU (1) | AU2009270697A1 (en) |
BR (1) | BRPI0916228A2 (en) |
CA (1) | CA2730940A1 (en) |
IL (1) | IL210696A (en) |
MX (1) | MX2011000652A (en) |
SG (1) | SG195572A1 (en) |
WO (1) | WO2010009453A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8277842B1 (en) | 2012-01-20 | 2012-10-02 | Dart Neuroscience (Cayman) Ltd. | Enteric-coated HT-2157 compositions and methods of their use |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770658B2 (en) * | 1998-09-09 | 2004-08-03 | Inflazyme Pharmaceuticals Ltd. | Substituted γ-phenyl-Δ-lactams and uses related thereto |
EP1161525A2 (en) * | 1999-03-12 | 2001-12-12 | Brown University Research Foundation | Methods and compositions for regulating memory consolidation |
ES2323940T3 (en) * | 2000-05-01 | 2009-07-28 | Accera, Inc. | USE OF MEDIUM CHAIN TRIGLICERIDS FOR THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE. |
US20070179197A1 (en) * | 2000-05-01 | 2007-08-02 | Accera, Inc. | Compositions and methods for improving or preserving brain function |
JP2002020291A (en) * | 2000-06-30 | 2002-01-23 | Sumitomo Pharmaceut Co Ltd | Therapeutic agent for cognitive dysfunction |
WO2002013867A2 (en) * | 2000-08-10 | 2002-02-21 | Cold Spring Harbor Laboratory | Augmented cognitive training |
US20040224316A1 (en) * | 2000-08-10 | 2004-11-11 | Tully Timothy P. | Augmented cognitive training |
EP1551855B1 (en) * | 2002-06-25 | 2012-01-04 | Helicon Therapeutics, Inc. | Altering memory by affecting staufen function |
US7642281B2 (en) * | 2002-08-07 | 2010-01-05 | Helicon Therapeutics, Inc. | Indolone compounds useful to treat cognitive impairment |
AU2003258287A1 (en) * | 2002-08-19 | 2004-03-03 | Helicon Therapeutics, Inc. | Screening methods for cognitive enhancers |
AU2006326040B2 (en) * | 2005-12-15 | 2012-02-09 | Société des Produits Nestlé S.A. | Compositions and methods for preserving brain function |
EP2001293B9 (en) * | 2006-04-03 | 2019-04-17 | Accera, Inc. | Use of ketogenic compounds for treatment of age-associated memory impairment |
SG172602A1 (en) * | 2006-05-19 | 2011-07-28 | Helicon Therapeutics Inc | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
GB0611458D0 (en) * | 2006-06-09 | 2006-07-19 | Univ Cambridge Tech | Assessment of functional status |
JP2009541493A (en) * | 2006-06-26 | 2009-11-26 | ヘリコン セラピューティクス,インコーポレイテッド | Method for modulating neurite outgrowth by use of a galanin-3 receptor antagonist |
-
2009
- 2009-07-17 CA CA2730940A patent/CA2730940A1/en not_active Abandoned
- 2009-07-17 AU AU2009270697A patent/AU2009270697A1/en not_active Abandoned
- 2009-07-17 KR KR1020117003456A patent/KR20110049801A/en not_active Application Discontinuation
- 2009-07-17 BR BRPI0916228A patent/BRPI0916228A2/en not_active IP Right Cessation
- 2009-07-17 JP JP2011518952A patent/JP5789511B2/en not_active Expired - Fee Related
- 2009-07-17 WO PCT/US2009/051082 patent/WO2010009453A1/en active Application Filing
- 2009-07-17 MX MX2011000652A patent/MX2011000652A/en not_active Application Discontinuation
- 2009-07-17 EP EP20090798843 patent/EP2313098A4/en not_active Ceased
- 2009-07-17 SG SG2013077730A patent/SG195572A1/en unknown
- 2009-07-17 CN CN2009801347276A patent/CN102143749A/en active Pending
-
2011
- 2011-01-17 IL IL210696A patent/IL210696A/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016119519A (en) | Heteroaryl Compounds as BTK Inhibitors and Their Use | |
RU2016151727A (en) | NEUROACTIVE STEROIDS, COMPOSITIONS AND THEIR APPLICATIONS | |
JP2007508361A5 (en) | ||
BRPI0610219A2 (en) | methods of treating a human being with cancer and pharmaceutical composition | |
JP2010530431A5 (en) | ||
CN104981458A (en) | Inhibitors of histone demethylases | |
CN103080111A (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | |
JP2013542929A5 (en) | ||
JP5954890B2 (en) | Sustained release formulation comprising 2-oxo-1-pyrrolidine derivative | |
JP2009526821A (en) | Novel pharmaceutical composition for the treatment of attention deficit hyperactivity disorder | |
JP7252390B2 (en) | Tasimelteon for treating Smith-Magenis syndrome | |
RU2016101958A (en) | PYROSOLIC COMPOUNDS AS FSHR MODULATORS AND THEIR APPLICATION | |
Terauchi et al. | Distinct roles of nitric oxide synthases and interstitial cells of Cajal in rectoanal relaxation | |
JP2012516349A5 (en) | ||
JP2010530002A5 (en) | ||
JP2020075933A (en) | Medicine for preventing and/or treating stress-induced diseases | |
JP2017526724A5 (en) | ||
JP2011528667A5 (en) | ||
RU2005129992A (en) | 4- (2-Phenyloxazol-4-ylmethoxy) cyclohexyloxy) butane acid derivatives and related compounds as PPAR modulators for the treatment of type 2 diabetes and atherosclerosis | |
KR20180011772A (en) | The novel amido heteroaryl aroyl hydrazide ethyne | |
JP2018504380A5 (en) | ||
JP4611308B2 (en) | Treatment of gastrointestinal dysfunction and associated stress using enantiomerically pure (R) 2,3-benzodiazepines | |
JP6051431B2 (en) | 5-HT4 receptor agonists that function as gastrointestinal motility promoters | |
JP2012502014A5 (en) | ||
BRPI0620885A2 (en) | imidazo [1,2-a] pyridin-3-yl acetic acid hydrazides, processes for their preparation and pharmaceutical uses thereof |